RxDoctor Payments Data

Larry Horesh, MD

Vascular & Interventional Radiology · Savannah, GANPI 1154398709

Payments from drug & device makers

What this record shows

The money is spread across several categories — other (51.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Angiodynamics, Inc. at 57.5% of the total. Reporting peaked in 2024 at $13,627 and has fallen 79.8% since, to $2,759 in 2025.

$28,928in general payments, 2019–2025

Across 398 payments — averaging $72.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$17K
  • W. L. Gore & Associates, Inc.$5K
  • Inari Medical, Inc.$1K
  • Endologix LLC$1K
  • Imperative Care, Inc$806
  • Medtronic$745
  • plus $4K from 33 others

What the payments were for

  • Travel & lodging$2,6939%
  • Food & beverage$11,19939%
  • Education$460%
  • Other$14,99052%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,928 in reported general payments places this provider in the 85th percentile of 120 vascular & interventional radiology providers in Georgia.

See all vascular & interventional radiology providers in Georgia

Medicare billing

Part B allowed, 2024
$941,586
Medicare patients
508
Services billed
10,219

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban335$278,952
XareltoRivaroxaban119$122,883
Enoxaparin Sodium16$3,463
ClopidogrelClopidogrel Bisulfate301$2,959
Cilostazol59$832
Potassium Chloride66$748
Pregabalin39$497
Atorvastatin Calcium56$418
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen30$376
Lactulose34$303
Rosuvastatin Calcium38$279
Furosemide67$254
Bumetanide13$201
Gabapentin27$195
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen16$154

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$12$278,952335 claims
Johnson & JohnsonXarelto$444$122,883119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 120 vascular & interventional radiology providers in Georgia.

Other vascular & interventional radiology in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →